CEP290 and Leber congenital amaurosis: In addition, an ongoing clinical trial uses a single AAV for subretinal delivery of SaCas9 double sgRNA has been lunched to delete a pathogenic mutation in the CEP290 gene in patients with Leber congenital amaurosis 10 [258].